362 related articles for article (PubMed ID: 12805079)
1. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.
Achan V; Broadhead M; Malaki M; Whitley G; Leiper J; MacAllister R; Vallance P
Arterioscler Thromb Vasc Biol; 2003 Aug; 23(8):1455-9. PubMed ID: 12805079
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans.
Kielstein JT; Impraim B; Simmel S; Bode-Böger SM; Tsikas D; Frölich JC; Hoeper MM; Haller H; Fliser D
Circulation; 2004 Jan; 109(2):172-7. PubMed ID: 14662708
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
Dayoub H; Rodionov RN; Lynch C; Cooke JP; Arning E; Bottiglieri T; Lentz SR; Faraci FM
Stroke; 2008 Jan; 39(1):180-4. PubMed ID: 18063827
[TBL] [Abstract][Full Text] [Related]
4. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH
Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
Matsuguma K; Ueda S; Yamagishi S; Matsumoto Y; Kaneyuki U; Shibata R; Fujimura T; Matsuoka H; Kimoto M; Kato S; Imaizumi T; Okuda S
J Am Soc Nephrol; 2006 Aug; 17(8):2176-83. PubMed ID: 16807406
[TBL] [Abstract][Full Text] [Related]
7. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA
Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
9. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans.
Chobanyan K; Thum T; Suchy MT; Zhu B; Mitschke A; Gutzki FM; Beckmann B; Stichtenoth DO; Tsikas D
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):32-41. PubMed ID: 17825631
[TBL] [Abstract][Full Text] [Related]
10. Regulation of fluid reabsorption in rat or mouse proximal renal tubules by asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase 1.
Bell T; Araujo M; Luo Z; Tomlinson J; Leiper J; Welch WJ; Wilcox CS
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F74-F78. PubMed ID: 29513072
[TBL] [Abstract][Full Text] [Related]
11. Specific Lowering of Asymmetric Dimethylarginine by Pharmacological Dimethylarginine Dimethylaminohydrolase Improves Endothelial Function, Reduces Blood Pressure and Ischemia-Reperfusion Injury.
Lee Y; Mehrotra P; Basile D; Ullah M; Singh A; Skill N; Younes ST; Sasser J; Shekhar A; Singh J
J Pharmacol Exp Ther; 2021 Feb; 376(2):181-189. PubMed ID: 33214214
[TBL] [Abstract][Full Text] [Related]
12. Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterolemia type II.
Chobanyan-Jürgens K; Fuchs AJ; Tsikas D; Kanzelmeyer N; Das AM; Illsinger S; Vaske B; Jordan J; Lücke T
Amino Acids; 2012 Aug; 43(2):805-11. PubMed ID: 22075968
[TBL] [Abstract][Full Text] [Related]
13. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure.
Ohnishi M; Wada A; Tsutamoto T; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Wang X; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():241S-244S. PubMed ID: 12193095
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
Desai A; Zhao Y; Warren JS
Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
[TBL] [Abstract][Full Text] [Related]
15. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
[TBL] [Abstract][Full Text] [Related]
16. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
Selley ML
J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
[TBL] [Abstract][Full Text] [Related]
17. The combined ratios of L-arginine and asymmetric and symmetric dimethylarginine as biomarkers in spontaneously hypertensive rats.
Hsu CN; Huang LT; Lau YT; Lin CY; Tain YL
Transl Res; 2012 Feb; 159(2):90-8. PubMed ID: 22243793
[TBL] [Abstract][Full Text] [Related]
18. Dimethylarginine dimethylaminohydrolase (DDAH)--a critical regulator of hypertensive left ventricular hypertrophy?
Bai Y; Hui R
Med Hypotheses; 2008; 70(5):962-6. PubMed ID: 17983707
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Liu X; Xu X; Shang R; Chen Y
Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
[TBL] [Abstract][Full Text] [Related]
20. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
